Market Overview

Investigation Report on China's Recombinant Human Lutropin alfa Market, 2018-2022 - ResearchAndMarkets.com

Share:

The "Investigation
Report on China's Recombinant Human Lutropin alfa Market, 2018-2022"

report has been added to ResearchAndMarkets.com's
offering.

According to the WHO's estimate, infertility affects 15% to 20% of the
global population. Survey data shows that in 2017, the incidence of
infertility among married couples in China was 10%, more than double the
4.8% in 1984. As environmental pollution intensifies and lifestyle
changes, the incidence of infertility is increasing and infertility is
increasingly prevalent among Chinese young people. About 15% to 20%
women of childbearing age in China are troubled by infertility.

As the biggest cause of female infertility in China, follicular
dysplasia syndrome resulting from endocrine dysfunction accounts for
over 40% of infertility cases. In addition to reasonable adjustments to
menstrual period and etiological treatment, for fertilization, it is
necessary to adopt an ideal solution to promote the development and
maturation of follicles in clinical treatment.

Since 2015 when the Chinese government relaxed its family planning
policy, sex hormone drugs have been growing rapidly, and the infertility
treatment and IVF, an assisted reproductive technology (ART), have
attracted much attention. In China's end markets of ART and sex hormone
drugs, macromolecular bioengineered drugs such as Recombinant Human
Follitropin, Recombinant Follitropin Beta, Recombinant Human Chorionic
Gonadotropin, and Human Lutropin alfa are taking the place of
small-molecule chemicals.

Recombinant Human Lutropin alfa is a glycoprotein obtained by genetic
engineering technique. It can combine with the luteinizing
hormone/chorionic gonadotropin (LH/CG) receptor on the ovariole sheath
(and granular layer) and the Leydig cell membrane. For women who lack
luteinizing hormone and follicle-stimulating hormone (FSH) to ovulate,
the use of LH can increase the level of estradiol secreted by the
follicle and stimulate follicular development.

Merck Serono's Recombinant Human Lutropin alfa (trade name: Luveris) was
approved to be sold in China in 2008. In 2017, the sales value exceeded
CNY 30 million. By the end of 2018, China's Recombinant Human Lutropin
alfa market will be monopolized by Merck Serono.

According to this analysis, multinational companies such as Merck Serono
and Merck Sharp & Dohme dominate China's fertility drug market.
Meanwhile, Chinese companies such as Livzon Pharmaceutical Group Inc.,
GeneScience Pharmaceuticals Co., Ltd., Zhejiang Xianju Pharmaceutical
Co., Ltd., Hybio Pharmaceutical Co., Ltd., and Chia Tai Tianqing
Pharmaceutical Group Co., Ltd. are also launching generic drugs. It is
expected that the pattern of China's Recombinant Human Lutropin alfa
market will change in the next few years.

In 2015, the Chinese government relaxed its family planning policy that
had been implemented for over three decades, allowing each couple to
have two children. In China, about 90 million women of childbearing age
are eligible to have a second child. And an estimated 30% of them have
the desire. Therefore, China's fertility drug market is promising.

Topics Covered

  • Situation of infertility in China
  • Overview of China's fertility drug market
  • Analysis on the fertility drug manufacturers in China
  • Major factors influencing the development of fertility drugs in China
  • Forecast on China's Recombinant Human Lutropin alfa market from 2018
    to 2022

List of Chapters

1 Relevant Concepts of Recombinant Human Lutropin alfa

2 Sales of Recombinant Human Lutropin alfa in China, 2013-2017

3 Analysis of Major Recombinant Human Lutropin alfa Manufacturers in
China, 2013-2017

4 Prices of Recombinant Human Lutropin alfa in China, 2017-2018

5 Prospect of China's Recombinant Human Lutropin Alfa Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/r7q9m2/investigation?w=4

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com